A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia

Rupa Narayan, Traci M Blonquist, Ashkan Emadi, Robert P Hasserjian, Meghan Burke, Christopher Lescinskas, Donna S Neuberg, Andrew M Brunner, Gabriela Hobbs, Hanno Hock, Steven L McAfee, Yi-Bin Chen, Eyal Attar, Timothy A Graubert, Christina Bertoli, Jenna A Moran, Meghan K Bergeron, Julia E Foster, Aura Y Ramos, Tina T Som, Megan K Vartanian, Jennifer L Story, Kristin McGregor, Molly Macrae, Tanya Behnan, Margaret C Wey, Jessica Rae, Frederic I Preffer, Patricia Lesho, Vu H Duong, Mason L Mann, Karen K Ballen, Christine Connolly, Philip C Amrein, Amir T Fathi, Rupa Narayan, Traci M Blonquist, Ashkan Emadi, Robert P Hasserjian, Meghan Burke, Christopher Lescinskas, Donna S Neuberg, Andrew M Brunner, Gabriela Hobbs, Hanno Hock, Steven L McAfee, Yi-Bin Chen, Eyal Attar, Timothy A Graubert, Christina Bertoli, Jenna A Moran, Meghan K Bergeron, Julia E Foster, Aura Y Ramos, Tina T Som, Megan K Vartanian, Jennifer L Story, Kristin McGregor, Molly Macrae, Tanya Behnan, Margaret C Wey, Jessica Rae, Frederic I Preffer, Patricia Lesho, Vu H Duong, Mason L Mann, Karen K Ballen, Christine Connolly, Philip C Amrein, Amir T Fathi

Abstract

Background: Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high interest. Brentuximab vedotin (BV) is an antibody-drug conjugate that is specific for human CD30. In this phase 1 dose escalation study, the authors evaluated the safety of BV combined with mitoxantrone, etoposide, and cytarabine (MEC) re-induction chemotherapy for patients with CD30-expressing R/R AML.

Methods: Using a standard dose escalation design, the authors evaluated 3 dose levels of BV (0.9 mg/kg, 1.2 mg/kg, and 1.8 mg/kg) administered once on day 1 followed by MEC on days 3 through 7.

Results: There were no dose-limiting toxicities noted and the maximum tolerated dose was not reached. The recommended phase 2 dose of BV was determined to be 1.8 mg/kg when combined with MEC. The side effect profile was similar to that expected from MEC chemotherapy alone, with the most common grade ≥3 toxicities being febrile neutropenia, thrombocytopenia, and anemia (toxicities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). Among the 22 patients enrolled on the trial, the composite response rate was 36%, with a composite response rate of 42% noted among those who received the highest dose of BV. The median overall survival was 9.5 months, with a median disease-free survival of 6.8 months observed among responders. Approximately 55% of patients were able to proceed with either allogeneic hematopoietic stem cell transplantation or donor lymphocyte infusion.

Conclusions: The combination of BV with MEC was found to be safe in patients with CD30-expressing R/R AML and warrants further study comparing this combination with the use of MEC alone in this population (ClinicalTrials.gov identifier NCT01830777).

Lay summary: The outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) are exceptionally poor. New and emerging treatment combinations are actively being studied in an effort to improve outcomes. The authors examined the combination of brentuximab vedotin, an antibody product that recognizes a marker called CD30, with mitoxantrone, etoposide, and cytarabine (MEC), a common chemotherapy regimen, in patients with R/R AML that expressed the CD30 marker. The authors found that the combination was safe and well tolerated. Future studies comparing this new combination with the use of MEC alone can help to inform its effectiveness for this patient population.

Keywords: CD30; Ki-1 antigen; acute myeloid leukemia; antibody-drug conjugate; brentuximab vedotin; cytarabine; etoposide; immunoconjugate; mitoxantrone; refractory; relapsed.

© 2019 American Cancer Society.

References

    1. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013;31:1293-1301. doi:10.1200/JCO.2011.40.5977
    1. Ganzel C, Sun Z, Cripe LD, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol. 2018;93:1074-1081. doi:10.1002/ajh.25162
    1. Medeiros BC. Is there a standard of care for relapsed AML? Best Pract Res Clin Haematol. 2018;31:384-386. doi:10.1016/j.beha.2018.09.006
    1. Link H, Freund M, Diedrich H, et al. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia. Haematol Blood Transfus. 1990;33:322-325.
    1. Bjorkholm M, Bjornsdottir J, Stenke L, Grimfors G. Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia. Oncology. 1990;47:112-114. doi:10.1159/000226800
    1. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23:4110-4116. doi:10.1200/JCO.2005.09.133
    1. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004;22:1078-1086. doi:10.1200/JCO.2004.07.048
    1. Kohrt HE, Patel S, Ho M, et al. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Am J Hematol. 2010;85:877-881. doi:10.1002/ajh.21857
    1. Tallman MS, Lee S, Sikic BI, et al. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. Cancer. 1999;85:358-367.
    1. Advani AS, Cooper B, Visconte V, et al. A phase 1/2 trial of MEC (mitoxantrone, etoposide, cytarabine) in combination with ixazomib for relapsed/refractory acute myeloid leukemia. Clin Cancer Res. 2019;25:4231-4237. doi:10.1158/1078-0432.CCR-18-3886
    1. DeAngelo DJ, Brunner AM, Werner L, et al. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018;93:254-261. doi:10.1002/ajh.24968
    1. Halpern AB, Othus M, Huebner EM, et al. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Leukemia. 2017;31:2560-2567. doi:10.1038/leu.2017.165
    1. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458-1465. doi:10.1182/blood-2003-01-0039
    1. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16:888-897. doi:10.1158/1078-0432.CCR-09-2069
    1. de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18:5845-5849. doi:10.1158/1078-0432.CCR-12-1803
    1. Fathi AT, Preffer FI, Sadrzadeh H, et al. CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis. Leuk Lymphoma. 2013;54:860-863. doi:10.3109/10428194.2012.728596
    1. Zheng W, Medeiros LJ, Hu Y, et al. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013;13:307-314. doi:10.1016/j.clml.2012.12.006
    1. Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649. doi:10.1200/JCO.2003.04.036
    1. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447. doi:10.1182/blood-2016-08-733196
    1. Zhao B, Chen R, O’Connor OA, et al. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol. 2016;82:696-705. doi:10.1111/bcp.12988
    1. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18:248-255. doi:10.1158/1078-0432.CCR-11-1425
    1. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812-1821. doi:10.1056/NEJMoa1002965
    1. Litzow MR, Wang XV, Carroll MP, et al. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. Am J Hematol. 2019;94:111-117. doi:10.1002/ajh.25333
    1. Blum KA. CD30: seeing is not always believing. Blood. 2015;125:1358-1359. doi:10.1182/blood-2015-01-622480
    1. Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology. 2016;69:155-158. doi:10.1111/his.12914
    1. Purdue MP, Lan Q, Martinez-Maza O, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood. 2009;114:2730-2732. doi:10.1182/blood-2009-04-217521
    1. Pavlov I, Martins TB, Delgado JC. Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. Clin Vaccine Immunol. 2009;16:1327-1331.
    1. Ferrara F, Lessi F, Vitagliano O, Birkenghi E, Rossi G. Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers (Basel). 2019;11(2). doi:10.3390/cancers11020224

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere